Zobrazeno 1 - 10
of 42
pro vyhledávání: '"O. V. Kotel'nikova"'
Autor:
O. V. Kotel’nikova, Yu. A. Prokopenko, A. A. Zinchenko, O. A. Razgulyaeva, E. A. Nokel’, D. M. Karlinsky, L. S. Zhigis, L. D. Rumsh
Publikováno v:
Bulletin of Experimental Biology and Medicine. 173:687-690
Autor:
O. V. Kotel’nikova, Yu. A. Prokopenko, A. A. Zinchenko, O. A. Razgulyaeva, E. A. Nokel’, D. M. Karlinsky, L. S. Zhigis, L. D. Rumsh
Publikováno v:
Bulletin of Experimental Biology and Medicine. 173:429-432
Autor:
D. M. Karlinsky, Yu. A. Prokopenko, L. S. Zhigis, A. A. Zinchenko, Lev D. Rumsh, O. V. Kotel’nikova
Publikováno v:
Russian Journal of Bioorganic Chemistry. 47:805-814
Abstract The review covers the study of the protective properties of IgA1 protease and the possibility of creating a vaccine preparation for the prevention of bacterial meningitis of various origins on its basis. Bacterial meningitis belongs to the g
Autor:
E. A. Nokel, O. V. Kotel’nikova, V. S. Zueva, A. P. Alliluev, Marina Tokarskaya, Natalia Yastrebova, Lev D. Rumsh, O. A. Razgulyaeva, E. I. Gordeeva, T. D. Melikhova, E. N. Kaliberda, L. S. Zhigis, Yuri Prokopenko, A. A. Zinchenko
Publikováno v:
Microbes and Infection. 21:336-340
Immunization of mice with recombinant IgA1 protease of Neisseria meningitidis or several structural derivatives thereof protects the animals infected with a variety of deadly pathogens, including N. meningitidis serogroups A, B, and C and 3 serotypes
Autor:
Lev D. Rumsh, V. S. Zueva, Yu. A. Prokopenko, A. P. Alliluev, L. S. Zhigis, O. A. Razgulyaeva, A. A. Zinchenko, T. D. Melikhova, O. V. Kotel’nikova, E. A. Nokel, E. A. Gordeeva
Publikováno v:
Bulletin of Experimental Biology and Medicine. 165:763-766
We studied immunogenicity of two recombinant proteins FR.9 and FR.11-3 created on the basis of fragments of the primary structure of N. meningitidis IgA1 protease with different molecular weights containing different sets of T and B epitopes. The pro
Autor:
L. S. Zhigis, V. S. Zueva, Yu. A. Prokopenko, O. V. Kotel’nikova, O. A. Razgulyaeva, A. P. Alliluev, A. A. Zinchenko, E. A. Gordeeva, O. V. Serova, T. D. Melikhova, Lev D. Rumsh, E. A. Nokel
Publikováno v:
Russian Journal of Bioorganic Chemistry. 44:64-72
Four recombinant proteins, MA28–P1004LEH6, ME135–H328LEH6, MW329–H622LEH6 and MH835–P1004LEH6, were prepared based on the genomic sequence of IgA1 protease from Neisseria meningitidis serogroup B strain H44/76. The immunogenic and protective
Autor:
E. Yu. Drozhzhina, O. V. Kotel’nikova, O. A. Razgulyaeva, Lev D. Rumsh, Yu. A. Prokopenko, A. P. Alliluev, E. A. Nokel, A. A. Zinchenko, T. D. Melikhova, L. S. Zhigis
Publikováno v:
Эпидемиология и вакцинопрофилактика, Vol 15, Iss 6, Pp 88-94 (2016)
The immunogenic and protective activities of recombinant IgA1 serine protease obtained on the base of the genome DNA of N. meningitidis serogroup B strain H44/76 were studied. A several recombinant proteins of different molecular weights that are bas
Autor:
E.А. Nokel, O. A. Razgulyaeva, A. A. Zinchenko, O. V. Kotel’nikova, Yu. A. Prokopenko, Lev D. Rumsh, L. S. Zhigis
Publikováno v:
Сonference proceedings.
Autor:
L. S. Zhigis, E. Yu. Yagudaeva, E. Yu. Drozhzhina, E. A. Sitnikova, A. A. Zinchenko, V. S. Zueva, I. S. Koroleva, O. A. Razgulyaeva, T. D. Melikhova, E. A. Nokel, E. A. Gordeeva, A. P. Alliluev, O. V. Kotel’nikova, Lev D. Rumsh, O. V. Serova
Publikováno v:
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 7:305-310
The study of enzymatic and protective properties of recombinant IgA1 protease in active and mutant form showed that active form of IgA1 protease exhibited species - and type-specificity for mouse and human immunoglobulins. Mutant form, which did not
Autor:
A. P. Alliluev, O. A. Razgulyaeva, A. M. Bichucher, Lev D. Rumsh, O. V. Kotel’nikova, E.E. Melnikov, Vitaly P. Zubov, E. Yu. Yagudaeva, L. S. Zhigis, L. V. Kozlov, V. S. Zueva, A. E. Avakov
Publikováno v:
Russian Journal of Bioorganic Chemistry. 36:81-89
A method of the isolation and purification of IgA1 protease from a culture of Neisseria meningitidis serogroup A has been developed. Three inactivated intermediates of the production of the meningococcal vaccine, a culture liquid, as well as a supern